NEW YORK (GenomeWeb News) - Sequenom CEO Harry Stylli bought 13,313 shares of the company's stock at an average price of $1.86 per share for total proceeds of $24,964 on Aug. 11, according to documents filed with the Securities and Exchange Commission.
 
Since Aug. 7, he purchased 53,700 shares for total proceeds of $96,565. He currently owns 54,700 shares of Sequenom stock.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.